Project description
The biology of drug resistance in cancer
Achieving a cure in many types of cancer is hampered by the emergence of drug resistance. Before proceeding with smarter therapeutic strategies, we need to better understand residual disease after treatment and how drug-tolerant cells emerge and persist. To address these issues, the EU-funded PERSIST-SEQ project proposes to study the biology of therapeutic resistance in cancer at the single cell level. Using patient-derived organoids, mouse models and modelling techniques, researchers will profile individual cells and obtain fundamental knowledge on drug resistance in cancer. Results are expected to improve treatment decisions and patient clinical outcomes.
Objective
It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by developing best practices, standard operating procedures (SOPs), and high-quality FAIR data, with the ultimate aim to empower them to unravel therapeutic resistance. Such, that the community can identify urgently needed markers to predict, prevent, and target tumour resistance. Cancer takes 9.6 million lives each year, 90% of which result from untreatable metastatic relapse occurring after initially (seemingly) effective treatment. Therapeutic resistance is hence a primary cause of cancer death that clinically cannot be predicted, prevented, or treated. Addressing the urgent need for smarter therapeutic strategies is however held back by the lack of standardised experimental approaches that enable studying the biology of residual disease and drug tolerant persister cells in full detail. This need encompasses best practices for single-cell sequencing, advanced modelling techniques using patient-derived organoids and xenografts, and data FAIRification for integrated experiments. To address this need, PERSIST-SEQ brings together globally leading groups in single-cell sequencing technologies, cancer modelling and therapeutic resistance. Furthermore, the consortium has a broad range of clinical samples, cell lines, 3D models (PDX and PDOs) and mice models (GEMMs) at its disposal that can be leveraged to answer a broad range of emerging questions. This positions the consortium excellently to (1) design and standardise single-cell experimental approach to study the biology of therapeutic resistance and (2) initiate the largest single-cell profiling initiative on therapeutic resistance. Importantly, PERSIST-SEQ is organised such that it can quickly adapt to emerging insights and techniques during the project, and that ensures the capture of learnings in manners that stimulate replication of workflows elsewhere.
Fields of science
Keywords
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
3521 AL Utrecht
Netherlands
See on map
Participants (16)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1011 JV AMSTERDAM
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1066 CX Amsterdam
See on map
3584 CT Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
3521 AL Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
CB10 1SA SAFFRON WALDEN
See on map
Participation ended
10060 Candiolo To
See on map
3584 CM Utrecht
See on map
08028 Barcelona
See on map
08035 Barcelona
See on map
08907 Hospitalet De Llobregat
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
151 85 Sodertaelje
See on map
64293 Darmstadt
See on map
51373 Leverkusen
See on map
67400 Illkirch-Graffenstaden
See on map
79108 Freiburg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
20139 Milano
See on map